EEF1A1 Deacetylation Enables Transcriptional Activation of Remyelination by Duman, Mert et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EEF1A1 Deacetylation Enables Transcriptional Activation of
Remyelination
Citation for published version:
Duman, M, Vaquie, A, Nocera, G, Heller, M, Stumpe, M, Sankar, DS, Dengjel, J, Meijer, D, Yamaguchi, T,
Matthias, P, Zeis, T, Schaeren-Wiemers, N, Hayoz, A, Ruff, S & Jacob, C 2020, 'EEF1A1 Deacetylation
Enables Transcriptional Activation of Remyelination', Nature Communications.
<https://www.nature.com/articles/s41467-020-17243-z.pdf>
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Nature Communications
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 31. Jul. 2020
ARTICLE
EEF1A1 deacetylation enables transcriptional
activation of remyelination
Mert Duman 1,2, Adrien Vaquié 1, Gianluigi Nocera1,2, Manfred Heller3, Michael Stumpe1,
Devanarayanan Siva Sankar1, Jörn Dengjel 1, Dies Meijer 4, Teppei Yamaguchi 5, Patrick Matthias 5,
Thomas Zeis6, Nicole Schaeren-Wiemers 6, Antoinette Hayoz1, Sophie Ruff1 & Claire Jacob 1,2✉
Remyelination of the peripheral and central nervous systems (PNS and CNS, respectively) is a
prerequisite for functional recovery after lesion. However, this process is not always optimal
and becomes inefficient in the course of multiple sclerosis. Here we show that, when
acetylated, eukaryotic elongation factor 1A1 (eEF1A1) negatively regulates PNS and CNS
remyelination. Acetylated eEF1A1 (Ac-eEF1A1) translocates into the nucleus of myelinating
cells where it binds to Sox10, a key transcription factor for PNS and CNS myelination and
remyelination, to drag Sox10 out of the nucleus. We show that the lysine acetyltransferase
Tip60 acetylates eEF1A1, whereas the histone deacetylase HDAC2 deacetylates eEF1A1.
Promoting eEF1A1 deacetylation maintains the activation of Sox10 target genes and increases
PNS and CNS remyelination efficiency. Taken together, these data identify a major
mechanism of Sox10 regulation, which appears promising for future translational studies on
PNS and CNS remyelination.
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Many axons of the peripheral and central nervous systems(PNS and CNS, respectively) are myelinated. Two typesof myelinating cells, Schwann cells (SCs) in the PNS
and oligodendrocytes (OLs) in the CNS, build a thick myelin
sheath rich in lipids around axons, which provides axonal insu-
lation and saltatory nerve conduction1. Without myelin, the
nervous system is poorly functional and sensitive to degeneration,
thus myelin is critical for the function of the nervous system and
the maintenance of its integrity. Different disorders in humans
can lead to demyelination, hypomyelination, or dysmyelination.
Demyelination occurs after traumatic lesions, which can regen-
erate in the PNS, but not in the CNS2–4. In the CNS, the most
frequent demyelinating disease is an immune degenerative disease
called multiple sclerosis that progresses through successive
demyelinating lesions leading to permanent loss of function when
remyelination fails5–7. In particular, the efficiency of CNS
remyelination decreases dramatically with age, mainly due to a
differentiation defect of OL precursor cells (OPCs) into mature
myelinating OLs5,6,8. Other myelin disorders are inherited, such
as subtypes of Charcot-Marie-Tooth disease9–11, a large group of
peripheral neuropathies, and the group of leukodystrophies in the
CNS12, or occur after an infection such as the Guillain-Barré
syndrome13. Loss of myelin can also be secondary to diabetes,
toxic agents, or aging. In summary, many pathological states can
lead to myelin deficiency and thus to severe neurological dis-
abilities. To optimize functional recovery and prevent irreversible
loss of function, it is of utmost importance to identify treatments
that enhance remyelination after lesion14,15.
To enhance remyelination, it is crucial to understand the
mechanisms controlling this process. PNS and CNS myelination
mechanisms have been extensively studied and several tran-
scription factors are known to be involved16–18. In addition, post-
translational modifications including acetylation and methylation
have been recently shown to hold critical functions in regulating
transcription factor activity and gene expression during myeli-
nation and remyelination19–21. For instance, in OLs, the highly
homologous histone deacetylases HDAC1 and HDAC2 (HDAC1/
2) are required for differentiation and myelination22. Interest-
ingly, HDAC1, HDAC3, and HDAC10 can promote nuclear
localization of the transcription factor Olig1 by deacetylation and
thereby OL maturation23. Methylation marks, such as trimethy-
lation of histone H3 lysine 4 (H3K4me3), are also involved in the
myelination process. Indeed, H3K4me3, an activating methyla-
tion mark, accumulates at enhancers of promyelinating factors
such as Myrf and Olig2 and of myelin genes to promote OL
myelination24,25. In the PNS, HDAC4, together with HDAC3,
deacetylate and silence the promoter of cJun, an inducer of SC
demyelination, to promote myelination26, however, the loss of
HDAC3 leads to hypermyelination in adult mice and promotes
remyelination after PNS lesion27,28, suggesting a dual function for
HDAC3 in the myelination and remyelination processes. The
PRC2 complex, which adds repressive H3K27me3 marks, also
possesses a dual function: it is necessary to prevent hypermyeli-
nation, whereas it also maintains myelin integrity by repressing
injury-related genes29. Among the transcription factors that
regulate myelination and remyelination, Sox10 holds major
functions in both PNS and CNS30–32. Indeed, Sox10 activates the
transcription of promyelinating and myelin genes such as Oct6,
Krox20, and Myelin protein zero (P0) in SCs33–35, and Myrf and
Myelin basic protein (Mbp) in OLs36,37. The mechanisms that
control the activity and expression of Sox10 remain however
partially understood. We previously showed that HDAC1/2 act as
co-factors of Sox10 in SCs and are thereby critical for SC devel-
opment, myelination, and remyelination38–41. In the context of
remyelination, HDAC2 allows the recruitment of a multi-
functional protein complex containing Sox10 and the two
H3K9 demethylases KDM3A and JMJD2C to Oct6 and Krox20
genes to de-repress these Sox10 target genes and allow their
activation by Sox1041. In these previous studies, the direct dea-
cetylation target of HDAC1/2 that enables the formation of this
complex and thereby Sox10 activity remained however elusive.
Here we show that Sox10 nuclear localization and expression are
negatively regulated by eEF1A1, thereby controlling Sox10
activity. EEF1A (two highly homologous proteins eEF1A1 and
eEF1A2 coded by two different genes) is described as a major
translation elongation factor, however, several studies have
identified additional functions for this factor42. Indeed, eEF1A
has also been involved in the nuclear export of tRNAs, tran-
scriptional regulation, proteolysis, apoptosis, oncogenesis, and
viral propagation42–44. We demonstrate that the regulation of
Sox10 by eEF1A1 is controlled by acetylation. Indeed, Ac-eEF1A1
translocates to the nucleus to interact with Sox10 and drag it out
of the nucleus. We show here that HDAC2 deacetylates eEF1A1
in the nucleus, which induces its return to the cytoplasm and
maintains Sox10 on its target genes. In addition, we report that
theophylline, a known activator of HDAC2, decreases the levels of
Ac-eEF1A1, increases the expression of Sox10 and of Sox10 target
genes, and enhances the remyelination process in the PNS after a
traumatic lesion and in the CNS after a demyelinating lesion in
young adult and old mice.
Results
EEF1A1 is deacetylated by HDAC1/2 in SCs. Sox10 is robustly
downregulated at 1 day post sciatic nerve crush lesion (dpl) in
adult mice (Fig. 1a), a well-characterized experimental model of
PNS lesion where SCs rapidly demyelinate and convert into repair
cells to promote axonal regrowth. At 12dpl, once axons have
regrown, Sox10 is recruited to and activates its target gene
Krox2033,41, another major promyelinating factor45,46, to induce
the remyelination process, which is almost complete at 60dpl. We
previously showed that HDAC1 and HDAC2, which can com-
pensate for the loss of each other, are necessary for Sox10 func-
tions in the PNS, and that HDAC2 is primarily involved in this
process38,39,41. To identify direct targets of HDAC1/2, we col-
lected at 1dpl sciatic nerves of adult mice treated with the
HDAC1/2 inhibitor mocetinostat or its vehicle and analyzed the
levels of acetylated proteins by mass spectrometry41. Interestingly,
analysis by Protein Match Score Summation identified eEF1A1 as
a putative HDAC1/2 deacetylation target (Supplementary
Fig. 1a). To validate this, we ablated Hdac1/2 specifically in SCs
by crossing mice expressing the Cre recombinase under control of
the Dhh promoter (Dhh-Cre47) with mice expressing floxed
Hdac1 and Hdac2 (Hdac1fl/fl;Hdac2fl/fl38,48). We found strongly
increased levels of Ac-eEF1A in SCs of postnatal day (P)4 Dhh-
Cre;Hdac1fl/fl;Hdac2fl/fl knockout (dKO) nerves as compared to
Dhh-Cre-negative control littermates (Fig. 1b, c), while total
eEF1A1 levels were similar in control and dKO nerves (Fig. 1d),
indicating that eEF1A deacetylation depends on HDAC1/2 in
SCs. Consistently, HDAC1/2 inhibition using the HDAC1/2
inhibitor mocetinostat in primary SC cultures led to strongly
increased levels of Ac-eEF1A1, but not of Ac-eEF1A2 (Fig. 1e, f
and Supplementary Fig. 2). Mass spectrometry analyses revealed
that all detected acetylated peptides of eEF1A1 were significantly
more abundant in samples of mocetinostat-treated SCs as com-
pared to vehicle-treated SCs (Supplementary Data 1). eEF1A1 has
20 putative acetylation sites49. Mass spectrometry analyses
allowed us to detect 4 of these sites on K386, K219, K408, and
K273, which are located in different domains of eEF1A149. In
addition, the antibody we used in Fig. 1b, c, e, f showing strongly
increased levels of Ac-eEF1A in the absence of HDAC1/2 activity
is directed against eEF1A acetylated at K41. These findings
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suggest that eEF1A1 is globally acetylated in the absence of
HDAC1/2 activity and that other lysine in addition to the ones
detected by mass spectrometry and by the acetylK41-eEF1A
antibody that we used here are most likely simultaneously
acetylated in the absence of HDAC1/2 activity.
Ac-eEF1A1 drags Sox10 out of the nucleus. We found that
eEF1A1 acetylation is increased in SCs upon de-differentiation in
culture (Fig. 2a) and in sciatic nerves after lesion (Fig. 2b and
Supplementary Fig. 1b). While eEF1A1 is mainly localized in the
SC cytoplasm (Supplementary Fig. 3), we show that Ac-eEF1A1 is
localized in both nuclear and cytoplasmic fractions (Fig. 1e, f).
We found decreased nuclear levels of Sox10 in de-differentiated
as compared to differentiated SCs and partial re-localization of
Sox10 in the cytoplasmic compartment (Fig. 2c, d). In addition,
Ac-eEF1A co-immunoprecipitated with Sox10 in both compart-
ments, an interaction that was potentiated by HDAC1/2 inhibi-
tion in the nuclear compartment, which also led to a strong
decrease of Sox10 levels in the nucleus (Fig. 2d). In line with its
eEF1A1 deacetylating function, HDAC2 interacted with eEF1A1
in the nucleus of de-differentiated SCs in culture (Fig. 2e) and in
sciatic nerves after lesion (Fig. 2b). We show that Sox10 is tar-
geted to the proteasome in de-differentiated SCs (Fig. 3a and
Supplementary Movie 1) and that inhibition of the proteasome
results in increased Sox10 levels (Fig. 3b). Taking these data
together, we hypothesized that eEF1A1 can translocate to the
nucleus to interact with Sox10, drag it out of the nucleus and
target it to the proteasome for degradation. Indeed, overexpressed
eEF1A1, which interacts with Sox10 in both cytoplasm and
nucleus of de-differentiated SCs (Fig. 3c), leads to increased
cytoplasmic re-localization of Sox10 (Fig. 3d) and increased co-
localization of Sox10 with the proteasome in the cytoplasmic
compartment (Supplementary Fig. 4) within 24 h, and to strongly
decreased Sox10 levels within 3 days (Fig. 3e). In SCs cultured
under de-differentiating conditions, approximately 25% of
eEF1A1 is localized in the nucleus (Fig. 4a). To determine whe-
ther acetylation of eEF1A1 promotes its nuclear localization, we
mutated individual lysine (K) into glutamine (Q) residues, which
mimic acetylation. We chose K41, K179, and K273, which have
been experimentally verified and several times described to be
acetylated49. We found by subcellular fractionation that each
mutation leads to increased nuclear localization of eEF1A1
(Fig. 4a). Among those, K273Q mutation was the most efficient.
Consistently, the mutation of K273 into arginine (R), which
prevents acetylation, was the most efficient to reduce nuclear
localization of the protein (Fig. 4b). Interestingly, K273 is the only
K residue specific to eEF1A149. Indeed, in eEF1A2, K273 is
replaced by R, thereby preventing acetylation at this position.
Consistent with decreased nuclear localization of K273R mutant,
overexpression of this mutant resulted in a decreased percentage
of low Sox10-expressing SCs as compared to overexpression of
wild-type eEF1A1 (Fig. 4c). Surprisingly, K179R mutation had a
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Fig. 1 EEF1A1 is deacetylated by HDAC1/2 in SCs. a Sox10 Western blot and quantification normalized to GAPDH showing low Sox10 levels at 1dpl in
crushed as compared to contralateral sciatic nerves of adult mice. Paired two-tailed Student’s t-tests, p value= 0.008938, n= 8 animals per group.
b, c Co-immunofluorescence of Ac-eEF1A and S100 (SC marker) and DAPI (nuclei) labeling (b) and immunoprecipitation (IP) of eEF1A1 and Western blot
of Ac-eEF1A (c) in sciatic nerves of P4 control (Ctrl) and DhhCre;Hdac1;Hdac2 knockout (dKO) mice showing increased levels of Ac-eEF1A in the absence
of HDAC1/2 in SCs. n.s.= non-specific. d Western blot of total eEF1A1 and GAPDH (loading control) in sciatic nerves of P4 Ctrl and dKO mice and
quantification of eEF1A1 levels normalized to GAPDH levels showing no significant difference between the two groups. Paired one-tailed Student’s t-tests, p
value= 0.297774, n= 4 animals per group. e IP eEF1A1 followed by Western blot of Ac-eEF1A in nuclear and cytoplasmic fractions of primary SCs cultured
under de-differentiating conditions and treated with the HDAC1/2 inhibitor mocetinostat (Mocet.) or its vehicle (Veh.) for 3 days. Lamin A/C (nuclear
marker), GAPDH (cytoplasmic marker) and eEF1A1 Western blots on lysates used for IP show the inputs. f Immunofluorescence of Ac-eEF1A and DAPI
labeling in primary SCs cultured under de-differentiation conditions and treated with mocetinostat or its vehicle for 3 days. Arrowheads (b) and arrows
(f) show SC nuclei. Z-series projections (b) or single optical sections (f) are shown. b, f Representative images of 3 different animals per group or of 3
independent experiments are shown. b, d Data are presented as mean values ± SEM. Scale bars: 10 µm. Source data are provided as a Source Data file.
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similar effect as K273R on Sox10 levels (Fig. 4c). By analyzing
Sox10 levels only in cells where eEF1A1 or the mutants were
present in the nuclear compartment, we found that K179R pre-
vents the decrease of Sox10 levels even when localized in the
nucleus (Fig. 4d). In SCs cultured under proliferating conditions,
overexpressed eEF1A1 is in a large majority found in the cyto-
plasmic compartment (Fig. 4e). We show in these conditions that
the three K to Q mutations lead to increased nuclear localization
of eEF1A1 (Fig. 4e) and to decreased Sox10 levels (Fig. 4f). We
next tested which region of Sox10 protein is responsible for its
decreased stability in the presence of Ac-eEF1A1. To this aim, we
co-transfected HEK293 cells, which do not express Sox10, with
either wild-type Sox10 of different Sox10 mutants together with
K273Q eEF1A1 or with GFP as control. We show that expression
of K273Q eEF1A1 leads to decreased levels of wild-type Sox10,
Sox10-95 (mutant containing an insertion of 2 amino acids in the
HMG domain, which impairs DNA binding50), Sox10-MIC
(mutation resulting in a shorter protein containing the first 188
aminoterminal residues of Sox10, which include the HMG
domain50), and Sox10-HMG (containing only the HMG
domain51) (Supplementary Fig. 5a, b), indicating that the HMG
domain is sufficient for Ac-eEF1A1 to decrease Sox10 stability.
Similar to SCs, K273Q eEF1A1 co-immunoprecipitated with
wild-type Sox10 in HEK293 cells (Supplementary Fig. 5c). In
addition, K273Q eEF1A1 also co-immunoprecipitated with
Sox10-95 (Supplementary Fig. 5c). These data show that Ac-
eEF1A1 interacts with Sox10 in HEK293 cells such as in SCs and
that the two additional amino acids in the HMG domain do not
impair this interaction.
Taken together, these data indicate that acetylation of eEF1A1
at any of the three residues K41, K179 or K273 increases eEF1A1
nuclear localization and further decreases Sox10 levels and show
that K179 and K273 are key acetylation sites for eEF1A1 nuclear
localization and decrease of Sox10 levels.
Tip60 associates with Stat3 to acetylate eEF1A1. To understand
the mechanism that leads to eEF1A1 acetylation after sciatic
nerve crush lesion, we analyzed by mass spectrometry eEF1A1
binding partners in sciatic nerves at 2dpl compared to unlesioned
nerves. EEF1A1 is a major translation elongation factor42,44;
consistent with this, we detected several proteins involved in RNA
transport and metabolism as eEF1A1 putative binding partners.
Also consistent with a function of eEF1A1 interacting with the
proteasome52 and targeting proteins to the proteasome for
degradation, we identified the proteasome regulatory proteins
Proteasome activator subunits 1 and 2 as eEF1A1 putative
binding partners (Supplementary Data 2). In addition, this ana-
lysis suggested that putative binding partners were recruited to
eEF1A1 upon sciatic nerve crush lesion. Among those, Stat3
appeared as an interesting candidate to further investigate
because it has been shown to interact with eEF1A1 in other cells53
and with the histone acetyltransferase Tip60 in the cytoplasmic
compartment54, and is known to be expressed in SCs and acti-
vated after a sciatic nerve lesion55–61. We thus decided to further
investigate the potential involvement of Stat3 and Tip60 in
eEF1A1 acetylation. Consistent with previous findings53,54, Tip60
and Stat3 co-immunoprecipitated with eEF1A1 (Fig. 5a) and
Stat3 co-immunoprecipitated with Tip60 (Fig. 5b) in SCs. Tip60
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has a molecular weight of 60 kDa and the higher molecular
weight isoforms of Tip60 from ~75 to ~100 kDa are sumoylated
isoforms, which have been shown to have increased acetyl-
transferase activity (Supplementary Fig. 6 and Refs. 62,63). We
show that eEF1A1 and Stat3 interact with sumoylated Tip60 in
SCs (Fig. 5a, b). We found that Tip60 is mainly localized in the
cytoplasmic fraction of SCs cultured under de-differentiating
conditions (Fig. 5c). In addition, Tip60 is strongly upregulated
after a sciatic nerve crush lesion during SC de-differentiation
(Fig. 5d). We thus tested whether Tip60 is involved in eEF1A1
acetylation and Sox10 regulation in de-differentiated SCs. Indeed,
inactivating Tip60 with the specific Tip60 inhibitor TH1834
robustly decreased eEF1A1 acetylation (Fig. 5e) and Tip60
binding to eEF1A1 (Fig. 5a), and increased Sox10 levels (Fig. 5f).
Interestingly, downregulation of Stat3 by shRNA led to decreased
levels of sumoylated Tip60 (Fig. 5g), decreased interaction of
Tip60 with eEF1A1 (Fig. 5h) and decreased levels of Ac-eEF1A
(Fig. 5i). Taken together, these results indicate that Tip60
associates with Stat3 to acetylate eEF1A1 in the cytoplasm of de-
differentiating SCs early after a PNS lesion.
Theophylline enhances PNS remyelination. The mechanism of
action of eEF1A1 on Sox10 and its regulation by HDAC2 are
summarized in Fig. 6. We next aimed at using this mechanism to
enhance remyelination in vivo. We show here that overexpression
of wild-type eEF1A1 or of K273Q eEF1A1 in SCs cultured under
differentiation conditions robustly decreases the percentage of
Krox20-expressing SCs as compared to GFP-expressing SCs, and
that expression of the K273Q mutant decreases further this per-
centage as compared to wild-type eEF1A1-overexpressing cells
(Supplementary Fig. 7). Krox20 is a Sox10 target gene and a major
transcription factor for myelination in developing and adult
SCs45,46. These data thus suggest that eEF1A1 interferes with the
myelination program in SCs and shows that mimicking con-
stitutive acetylation of K273 increases this function. We hypo-
thesized that increasing the deacetylation rate of eEF1A1 by
increasing HDAC2 expression and activity would prevent Sox10
cytoplasmic re-localization and degradation and thereby maintain
the activation of Sox10 target genes (Fig. 6). Sox10 directly binds
to and activates the promyelinating factor genes Oct6 and Krox20
in SCs and Myrf in OLs and myelin genes such as P0 in SCs and
Mbp in both SCs and OLs30,32–34,36. We previously showed that
downregulation of HDAC2 in SCs by shRNA leads to decreased
levels of Sox10, Krox20, and P0, while overexpression of HDAC2
increases Sox10, Krox20, and P0 levels38. Theophylline is a
known pharmacological activator of HDAC2 at low dose,
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increasing both HDAC2 activity and expression, while at higher
concentrations theophylline acts as an antagonist of adenosine
receptors and as an inhibitor of phosphodiesterases64,65. We show
here that a low concentration of theophylline (1 µM) increases
HDAC2 and Sox10 levels in primary SCs, whereas 1 µM CGS
15943 (antagonist of adenosine receptors) or 500 µM IBMX
(inhibitor of phosphodiesterases) or 10 µM Rolipram (inhibitor of
type IV phosphodiesterases) either have no effect or decrease
HDAC2 and/or Sox10 levels (Supplementary Fig. 8a, b). At these
concentrations, CGS 15943, IBMX, and Rolipram are fully active
on their targets. These data show that theophylline does not
increase Sox10 levels through inhibiting phosphodiesterases or
antagonizing adenosine receptors but is very likely to induce its
effect on Sox10 through its third target HDAC2. Theophylline is
already used as a drug in humans to treat asthma and chronic
obstructive pulmonary disease65. Its activity, mode of adminis-
tration and toxicity are thus very well described in mice and
humans. To test whether theophylline enhances PNS remyeli-
nation, we carried out sciatic nerve crush lesions and treated mice
with theophylline at 10dpl, just before SCs start remyelinating
regenerated axons, for 2 or 4 consecutive days. We found that
theophylline treatment indeed increases HDAC2 expression
(Fig. 7a) and decreases Ac-eEF1A1 levels (Fig. 7b, c) as compared
to vehicle-treated mice. Consistently, Sox10 levels were also
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are provided as a Source Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17243-z
6 NATURE COMMUNICATIONS |         (2020) 11:3420 | https://doi.org/10.1038/s41467-020-17243-z | www.nature.com/naturecommunications
increased by theophylline treatment (Fig. 7a), which also led to
increased levels of Krox20 and P0 (Fig. 7a). Sox10 is recruited to
its target genes Krox20 (at the myelinating SC element, MSE) and
P0 (at the intron 1) at the SC redifferentiation stage to induce
remyelination (Fig. 7d). We show here that theophylline rapidly
promotes the recruitment of Sox10 to its target genes (Fig. 7e),
whereas the HDAC1/2 inhibitor mocetinostat impairs Sox10
recruitment (Fig. 7f), consistent with our previous findings
showing impaired remyelination after lesion in sciatic nerves
lacking HDAC1/2 in SCs41. To test whether theophylline also
increases Sox10 levels during developmental myelination, we
treated mouse pups with theophylline from P1 to P3 and col-
lected their sciatic nerves at P4. While theophylline had no effect
on the levels of Sox10, P0 or HDAC2 in Dhh-Cre dKO mice
lacking HDAC1/2 in SCs, we show that theophylline increases the
levels of Sox10, P0, and HDAC2 in control littermate (Dhh-Cre
negative) mice (Fig. 7g), indicating that theophylline can increase
Sox10 and P0 levels also during development and suggesting that
Nucl.Cyt.
(kDa)
50
250
75
100
150
0
0.5
1
250
75
50
100
150
100
75
37
100
75
75
50
37
50
37
37
(kDa)
(kDa)
(kDa)
(kDa)
(kDa)
(kDa)
250
75
50
100
150
(kDa)
(kDa)
37
75
100
37
75
50
75
75
100
100
IP eEF1A1
IP
Ctrl
IP
Stat3
eEF1A1
eEF1A1
GAPDH
Stat3
Stat3
Stat3
Reblot Stat3
Input
Input
Input
Veh. Tip60i
(kDa)
(kDa)
IP eEF1A1
Veh.
Veh.
Co Cr Co Cr Co
Co 1 dpl 3 dpl 5 dpl 12 dpl
Cr Co Cr
4
3
2
1
0
0
0.5
0.8
0.4
2.5
2
1.5
1
0.5
0
0
1Tip60i
Tip60i
IP eEF1A1
Ctrl
sh
Ctrl
sh
Stat3
sh
Stat3
sh
Stat3 sh Stat3 shCtrl sh
Sumoylated Non-sumoylated
Ctrl sh
IP eEF1A1
Veh. Tip60i
250
75
50
100
150
(kDa)
250
75
50
100
150
Vehicle Tip60
inhibitor
Tip60
Tip60
Tip60
Tip60
Tip60
Tip60
sumo-Tip60
GAPDH
GAPDH
GAPDH
GAPDH
Lamin
A/C
Ti
p6
0 
le
ve
ls
Co
nt
ro
l s
hR
NA
St
at
3 
sh
RN
A
Stat3
a
b
c
d
e
f
g
h i Ac-eEF1A Stat3/Ac-eEF1A Stat3/Ac-eEF1A/DAPI
Ti
p6
0 
le
ve
ls
Ac
-e
EF
1A
1 
le
ve
ls
Ti
p6
0 
le
ve
ls
So
x1
0 
le
ve
ls
Blot Tip60
Blot Tip60
Blot Ac-eEF1A
Ac-eEF1A1
Sox10
GAPDH
Vehicle
Vehicle
Tip60
inhibitor
Tip60
inhibitor 
Blot Tip60
1 dpl 3 dpl 12 dpl5 dpl
Fig. 5 Tip60 acetylates eEF1A1 in a Stat3-dependent manner. a, e eEF1A1 immunoprecipitation (IP) in lysates of SCs induced to de-differentiate for 1 day
and treated with TH1864 (Tip60 inhibitor, Tip60i) or vehicle, and Tip60, Stat3 (a) or Ac-eEF1A (e) Western blot and quantification (normalized to eEF1A1)
of Tip60 co-immunoprecipitated with eEF1A1 (a) or of Ac-eEF1A1 (e) in Tip60 inhibitor- compared to vehicle-treated SCs. b IP Stat3 or Flag (Ctrl) in lysates
of SCs induced to de-differentiate for 1 day, Tip60 Western blot and Stat3 inputs. c Tip60, GAPDH (cytoplasmic marker) and Lamin A/C (nuclear marker)
Western blots in cytoplasmic and nuclear fractions of SCs induced to de-differentiate for 1 day. Dashed lines: samples run on the same gel, but not on
consecutive lanes. d Tip60 and GAPDH Western blots in lysates of crushed (Cr) and contralateral (Co) mouse sciatic nerves at 1-3-5-12dpl, and Tip60
quantification normalized to GAPDH in Cr compared to Co. f Sox10 and GAPDH Western blots in lysates of SCs induced to de-differentiate and treated
with Tip60i or vehicle for 3 days and Sox10 quantification normalized to GAPDH. g Stat3 and Tip60 Western blots in SCs transduced with Stat3-specific
shRNA (Stat3 sh) or non-targeting control shRNA (Ctrl sh) lentiviruses and quantification of sumoylated (higher molecular weight) and non-sumoylated
(lower molecular weight) Tip60 isoforms normalized to GAPDH. h eEF1A1 IP and Tip60 Western blot in SCs transduced with Stat3 sh or Ctrl sh
lentiviruses. i Stat3 and Ac-eEF1A co-immunofluorescence and DAPI labeling in primary SCs transduced with Stat3 sh or Ctrl sh lentiviruses and induced to
de-differentiate for 2 days. Scale bar: 20 µm. Data presented as mean values ± SEM. Unpaired (f) or paired (a, d, e, g) one-tailed (gray asterisk) or two-
tailed (black asterisks) Student’s t-tests. P values= 0.029197 (a), 0.139771 (d, 1dpl), 0.047935 (d, 3dpl), 0.030298 (d, 5dpl), 0.061845 (d, 12dpl),
0.001796 (e), 0.033551 (f), 0.047979 (g, sumoylated), 0.300207 (g, non-sumoylated). N= 3 independent experiments or 3 animals per time-point. For
each panel, representative images of 3 independent experiments are shown. Source data are provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17243-z ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3420 | https://doi.org/10.1038/s41467-020-17243-z | www.nature.com/naturecommunications 7
this effect may require the presence of HDAC2 and/or HDAC1,
although we cannot exclude a potential inability of the Dhh-Cre
dKO mutants to express Sox10 and P0 with or without theo-
phylline or that theophylline may act through additional or other
pathways to increase Sox10 and P0 in control mice. In addition to
increasing the expression of HDAC2, Sox10, Krox20, and P0,
theophylline also increased myelin thickness (Fig. 8a) and led to
faster motor and sensory functions recovery (Fig. 8b), while there
was neither a difference in the density of SCs or of inflammatory
cells (Supplementary Fig. 9a) nor a difference in the percentage of
proliferating cells (Supplementary Fig. 9b). Consistently, theo-
phylline treatment did not alter the density of SCs in culture
(Supplementary Fig. 9c). Remyelinating sheaths are known to
remain thinner as compared to myelin sheaths of unlesioned
nerves, however, myelin in the injured nerve of theophylline-
treated mice, but not of vehicle-treated mice, recovered a similar
thickness as in uninjured nerves (Fig. 8c), indicating that theo-
phylline allows full remyelination after lesion. Taken together,
these data show that theophylline improves PNS remyelination
efficiency after lesion.
Ac-eEF1A1 regulates Sox10 levels in OLs. Similar to SCs, eEF1A
deacetylation in OLs depends on HDAC1/2 activity, as shown by
a robust increase of Ac-eEF1A in OLs of mouse spinal cords 24 h
after intrathecal injection of the HDAC1/2 inhibitor mocetinostat
(Fig. 9a) and in primary OLs treated with mocetinostat (Fig. 9b).
In addition, inactivating Tip60 with the specific Tip60 inhibitor
TH1834 strongly reduced the increase of Ac-eEF1A due to
mocetinostat treatment (Supplementary Fig. 10), suggesting that
Tip60 acetylates eEF1A1 also in OLs. Such as in SCs, treatment
with mocetinostat led to cytoplasmic relocalization of Sox10 and
to strongly decreased Sox10 levels in primary OLs (Fig. 9c).
Consistently, ablation of HDAC1/2 in mature OLs using the
tamoxifen-inducible PLP-CreERT2 mouse line led to increased
interaction of Ac-eEF1A with Sox10 (Fig. 9d) and to decreased
Sox10 levels (Fig. 9e, f). To test whether eEF1A1 has a similar
effect on Sox10 levels in OLs as in SCs, we overexpressed wild-
type eEF1A1 or K273Q mutant in the oligodendroglial Oli-neu
cell line66 that can be easily transfected. We and others have
shown that Oli-neu cells express high levels of MBP when cul-
tured in differentiating conditions for 3 days and acquire a
complex morphology after 10 days (Supplementary Fig. 11a and
Ref. 66). Consistent with our findings in SCs, K273Q mutant was
localized in both nuclear and cytoplasmic compartments of vir-
tually all transfected cells, while wild-type eEF1A1 was either
localized exclusively in the cytoplasm or in both nucleus and
cytoplasm of Oli-neu cells cultured under proliferating conditions
(Supplementary Fig. 11b). We show here that overexpression of
wild-type eEF1A1 or expression of K273Q mutant both decrease
Sox10 levels as compared to control GFP transfection (Supple-
mentary Fig. 11c, d) and that expression of K273Q mutant further
decreases Sox10 levels as compared to overexpression of wild-
type eEF1A1 (Supplementary Fig. 11c). Consistently, over-
expression of wild-type eEF1A1 or expression of K273Q mutant
both decreased MYRF levels as compared to control GFP trans-
fection (Supplementary Fig. 11e, f) and expression of K273Q
mutant further decreased MYRF levels as compared to over-
expression of wild-type eEF1A1 (Supplementary Fig. 11e). Of
note, K273Q mutant is re-localized to the cytoplasm of Oli-neu
cells upon induction of differentiation (Supplementary Fig. 11b),
possibly by a compensatory mechanism to recover Sox10
expression in the nucleus and thereby allow the induction of
differentiation. To test whether K273Q mutant indeed impairs
the induction of differentiation, we carried out luciferase gene
reporter assays of the Mbp promoter 5 min after the induction of
differentiation, where the activity of the Mbp promoter is already
increased as compared to proliferating conditions (Supplemen-
tary Fig. 11g), in Oli-neu cells expressing K273Q mutant or GFP
or overexpressing wild-type eEF1A1. While overexpression of
wild-type eEF1A1 led to a trend of decreased activity of the Mbp
promoter, expression of K273Q mutant decreased very sig-
nificantly the activity of the Mbp promoter (Supplementary
Fig. 1h), indicating that K273Q mutant impairs the activation of
the Sox10 target gene Mbp and thus suggesting that K273Q
mutant indeed impairs the induction of differentiation. At a later
time-point in the differentiation process when MBP is already
robustly expressed in Oli-neu cells (Supplementary Fig. 11a), we
show that overexpression of wild-type eEF1A1 also strongly
decreases the activation of the Mbp promoter (Supplementary
Fig. 11i). Taken together, these data show that Ac-eEF1A1 is
deacetylated by HDAC2 and negatively regulates the expression
of Sox10 and of the Sox10 target genes Myrf and Mbp in OLs.
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Theophylline enhances CNS remyelination. To test whether
theophylline enhances CNS remyelination, we carried out focal
demyelinating lesions in the spinal cord of adult mice using
lysolecithin injection, a widely used and well-characterized
experimental model of CNS demyelinating lesion where the
remyelination process starts at 14 days post demyelinating lesion
(dpdl). We show that a short treatment with theophylline from 10
to 14dpdl leads to a strong increase of HDAC2, Sox10 and MBP
expression (Fig. 9g) and to improved remyelination efficiency at
14 and 30dpdl in young adults (Fig. 9h) and also in old mice
(Fig. 9i), where remyelination efficiency is lower as compared to
young adults15. Theophylline induced remyelination in the lesion
site but did not affect myelination outside the lesion site, as
shown by unchanged g ratio (Fig. 9i, j). These data indicate that
theophylline improves CNS remyelination efficiency after lesion.
Discussion
Demyelination occurs in various cases in humans. In many cases,
the remyelination process is not efficient enough and the loss of
myelin leads to permanent loss of function. For this reason, it is
crucial to better understand how remyelination is controlled in
order to identify strategies that improve remyelination. In this
study, we have focused our analyses on the remyelination process
that occurs in the PNS after a traumatic lesion and in the CNS
after a demyelinating lesion. In particular, we identified a
mechanism that controls the activity and expression of Sox10, a
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Fig. 7 Theophylline increases Sox10, Krox20, and P0 expression and eEF1A1 deacetylation. a HDAC2 (12dpl: n= 3, p= 0.025883, 14dpl: n= 5, p=
0.011697), Sox10 (12dpl: n= 3, p= 0.031422, 14dpl: n= 3–4, p= 0.032671), Krox20 (12dpl: n= 3, p= 0.030486, 14dpl and 30dpl: n= 7, p= 0.033493
and 0.022041) and P0 (12dpl: n= 3, p= 0.022239, 14dpl: n= 4-5, p= 0.019084, 30dpl: n= 6, p= 0.0456) Western blots at 12, 14 and 30dpl in lysates of
crushed (Cr) or contralateral (Co) sciatic nerves of mice treated at 10dpl with theophylline (Theo) or vehicle (Veh.) for 2 days (12dpl) or 4 days (14 and
30dpl), and quantification normalized to GAPDH and Co. b, c EEF1A1 IP and Ac-eEF1A Western blot (b) and Ac-eEF1A and S100 (SC marker) co-
immunofluorescence and DAPI labeling (c) at 12dpl in Cr (c) or in Cr and Co (b) 20 h after one theophylline or vehicle injection, and (b) Ac-eEF1A1
quantification normalized to GAPDH input and Co in theophylline- compared to vehicle-treated groups. N= 3 animals per group (b, c), p= 0.000597 (b).
Representative images are shown. d–f GFP (d) and/or Sox10 (d–f) chromatin immunoprecipitation at 12dpl on Krox20MSE or P0 intron 1 in (d) Cr and fold
enrichment normalized to Sox10 input compared to GFP (n= 3 animals, Sox10 and GFP IPs on the same nerve lysate, pKrox20-MSE= 0.032616, pP0-
intron-1= 0.027702) or in Cr (e) collected 20 h after theophylline (Theo) or vehicle (Veh.) treatment or (f) after mocetinostat (Mocet.) or Veh. treatment
for 2 days. e N= 5–6 animals per group, pKrox20-MSE= 0.030466, pP0-intron-1= 0.04003. f N= 3 animals per group, pKrox20-MSE= 0.037396, pP0-
intron-1= 0.023672. g Sox10, P0, HDAC2, and GAPDH Western blots in lysates of P4 DhhCre;Hdac1fl/fl;Hdac2fl/fl dKO and control littermate sciatic
nerves treated at P1 with Theo or Veh. for 3 days, and quantification normalized to GAPDH in Theo compared to Veh. N= 6 animals per group, pSox10=
0.04567, pP0= 0.033358, pHDAC2= 0.02891. Dashed lines: samples loaded on the same gel but not on consecutive lanes. Data are presented as mean
values ± SEM. Paired (a: HDAC2 and Sox10-12dpl, Krox20-14dpl-30dpl; b, d, e, and f: P0-intron-1; g) or unpaired one-tailed (gray asterisks) or two-tailed
(black asterisks) Student’s t-tests. Scale bar: 20 µm (c). Source data are provided as a Source Data file.
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Fig. 8 Theophylline accelerates and enhances PNS remyelination and functional recovery. a, c Electron micrographs of Cr ultrathin sections at 14dpl,
30dpl (a) and 2mpl (c) from mice treated with theophylline or vehicle at 10dpl for 4 days, and myelin thickness quantification (g ratio) of remyelinated
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pRotarod= 0.489629, pToe-pinch=0.000363. Data are presented as mean values ± SEM. Unpaired one-tailed (gray asterisks) or two-tailed (black
asterisks) student’s t-tests. Scale bars: 5 µm (a, b), 10 µm (c). Source data are provided as a Source Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17243-z
10 NATURE COMMUNICATIONS |         (2020) 11:3420 | https://doi.org/10.1038/s41467-020-17243-z | www.nature.com/naturecommunications
major transcription factor of PNS and CNS myelination and
remyelination. We previously demonstrated that HDAC1/2 act as
co-factors of Sox1038-41, but the direct deacetylation mechanism
underlying this function remained unclear. We show here that
HDAC1/2 deacetylate eEF1A1, which prevents interaction of
eEF1A1 with Sox10 and re-localization of Sox10 to the cytoplasm,
thereby allowing Sox10 to activate its target genes and enabling
remyelination. We found that after a sciatic nerve crush lesion,
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Fig. 9 Theophylline promotes CNS remyelination in young and old adults. a Co-immunofluorescence of Ac-eEF1A and CC1 (marker of mature OLs) and
DAPI labeling in white matter of adult mouse spinal cord 24 h after treatment with mocetinostat or its vehicle. b, c Co-immunofluorescence of Ac-eEF1A
(b) or Sox10 (c) with CC1 and DAPI labeling in differentiated primary OLs treated with mocetinostat or its vehicle for 24 h. d–f Co-immunoprecipitation (IP)
of Ac-eEF1A with Sox10 (d) or Sox10 Western blot (e) and quantification normalized to GAPDH, or co-immunofluorescence of HDAC2 or Sox10 with CC1
and DAPI labeling (f) in spinal cords of PLPCreERT2;Hdac1fl/fl;Hdac2fl/fl (dKO) mice or control littermate (Ctrl) at 14 days post tamoxifen injections. g Co-
immunofluorescence of HDAC2, Sox10 and MBP and DAPI labeling in the spinal cord lesion site of adult mice (3–4-month old) at 14dpdl after a 4-day
treatment with theophylline (Theo) or its vehicle. Arrows indicate OLs. h–j Electron micrographs of spinal cord ultrathin sections in the lesion site (h, i) or
unlesioned site (i, j) at 14 and/or 30dpdl in young adult (4-month old) (h, j) or old (19-month old) (i) mice, and % of remyelinated axons in the lesion site
(delineated by axons with thin myelin, g ratio ≥ 0.835) or g ratio in unlesioned site. Data are presented as mean values ± SEM. Unpaired (h, i, j) or paired
(d, e) one-tailed (gray asterisk) or two-tailed (black asterisks) Student’s t-tests, p values: 0.047387 (d), 0.036845 (e), 0.043182 (h, 14dpl), 0.018162
(h, 30dpl), 0.127958 (i, unlesioned), 0.03517 (i, lesion), 0.328856 (j, 14dpl), 0.447458 (j, 30dpl). d n= 5 animals per group, (e) n= 3 animals per group,
(h–j) n= 3 animals per group per time-point. Representative images of 3 animals per group (a, f, g) or of 3 independent experiments (b, c) are shown.
Scale bars: white= 10 µm, black= 5 µM. Source data are provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17243-z ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3420 | https://doi.org/10.1038/s41467-020-17243-z | www.nature.com/naturecommunications 11
Tip60 is upregulated and acetylates eEF1A1 in the SC cytoplasm,
in a Stat3-dependent manner. Consistently, Stat3 has been pre-
viously shown to interact with cytoplasmic Tip6054 and with
eEF1A153 in other cells. We show here that Stat3 promotes the
interaction of Tip60 with eEF1A1 and eEF1A1 acetylation.
eEF1A1 is a major translation elongation factor, which is mostly
found in the cytoplasmic compartment. However, eEF1A1 has
been shown to have non-canonical functions and to be localized
in the nuclear compartment in some cases42–44. EEF1A1 can be
submitted to various post-translational modifications, including
phosphorylation, acetylation, methylation, ubiquitination49.
Phosphorylation, which is the most studied post-translational
modification of eEF1A1, has been shown to regulate eEF1A1
activity42. In contrast, the function of eEF1A1 acetylation is not
or poorly described. We show here that acetylation of eEF1A1
induces its re-localization to the nuclear compartment of SCs.
There are 20 putative acetylation sites in eEF1A149. We studied
the functions of the three acetylation sites K41, K179, and K273
because they have been several times verified experimentally. In
addition, K273 is found only in eEF1A1 and not in eEF1A249.
Our results indicate that acetylation at any of these sites promotes
nuclear localization of eEF1A1 and the decrease of Sox10 levels in
SCs, and suggest that K179 and K273 are key acetylation sites for
these functions. By using mocetinostat, a specific inhibitor of
HDAC1/2, or by ablating HDAC1/2 specifically in SCs or in OLs,
we show that HDAC1/2 are necessary to deacetylate eEF1A1 in
SCs and OLs, and to maintain high Sox10 expression in the
nuclear compartment of these cells.
In the aim of identifying a treatment that promotes this
mechanism and thereby potentially improves remyelination effi-
ciency, we tested the effect of theophylline treatment in vivo.
Although theophylline inhibits phosphodiesterases and antag-
onizes adenosine receptors when used at high concentration, it is
also a known potent activator of HDAC2, increasing HDAC2
activity and expression when used at low concentration64,65. We
show here that while theophylline increases the levels of HDAC2
and Sox10 in SCs, compounds that specifically inhibit phospho-
diesterases or antagonize adenosine receptors either have no
effect on HDAC2 and Sox10 levels or decrease the levels of
HDAC2 and Sox10, indicating that theophylline does not increase
Sox10 levels through its effect on phosphodiesterases or adeno-
sine receptors but is highly likely to act on Sox10 through
HDAC2. Interestingly, a short treatment with theophylline in
mice increased HDAC2 expression, decreased Ac-eEF1A1 levels,
increased the expression of Sox10 and its target genes and
improved remyelination efficiency in both PNS and CNS. Of
major importance, theophylline also increased the efficiency of
CNS remyelination in old mice, thereby suggesting a potential
beneficial effect on the remyelination process in aged individuals,
where remyelination is strongly impaired.
We previously showed that in differentiated primary SCs where
Sox10 levels are already high and which express the major pro-
myelinating factor Krox20 and the myelin protein P0, the over-
expression of Sox10 results in a 5-fold induction of the Krox20
MSE38, a critical enhancer for Krox20 expression. In addition,
overexpression of HDAC2 alone leads to a 3-fold induction of the
Krox20 MSE and co-overexpression of Sox10 and HDAC2 has a
synergistic effect on the activation of the Krox20 MSE, with a 25-
fold increase38. These data indicate that increased Sox10 levels in
differentiated SCs can further increase the activation of its target
gene Krox20 and that this is potentiated by simultaneous increase
of HDAC2 expression. In the case of remyelination, Sox10 is
upregulated at the remyelination stage to induce the remyelina-
tion program by the upregulation of Krox20 and of myelin pro-
teins. We show here that theophylline treatment at 10dpl before
remyelination starts allows to reach faster a high upregulation of
Sox10, faster recruitment of Sox10 to its target genes Krox20 and
P0, faster upregulation of Krox20 and P0, faster remyelination
and faster functional recovery. We also showed that theophylline
treatment does not change the density of SCs or of inflammatory
cells nor the percentage of proliferating cells in the sciatic nerve
after lesion. Upregulating Sox10 to a high level faster is thus very
likely to induce faster remyelination and faster functional
recovery. In addition, raising Sox10 to a higher expression level is
also likely to help sustain the remyelination process for a longer
time, as shown by the high expression of Krox20 and P0 at 30dpl
and more efficient remyelination in theophylline-treated mice at
2 months post lesion. Thus, our previous work38 and current
findings suggest that Sox10 levels and activity including the
timing of Sox10 upregulation and the levels of nuclear Sox10 are
rate-limiting for the speed and efficiency of remyelination, and
that increasing Sox10 levels and activity in conjunction with
HDAC2 appears as a very promising strategy to accelerate and
improve remyelination after lesion.
In summary, this study identifies Ac-eEF1A1 as a critical
negative regulator of the remyelination process and shows that
theophylline, by activating HDAC2, promotes eEF1A1 deacety-
lation, increases Sox10 levels and activity and remyelination speed
and efficiency after lesion of the PNS and CNS, thus appearing as
a very promising compound to test in future translational studies
to accelerate and promote remyelination after traumatic lesions
or in the context of demyelinating disorders.
Methods
Statistical analyses. For each data set presented, experiments were performed at
least three times independently or with at least three animals and p values were
calculated in Microsoft Excel (Mac version 16.34) using two-tailed (black asterisks)
or one-tailed (gray asterisks) Student’s t-tests. P values: *<0.05, **<0.01,
***<0.001, data are presented as mean values ± SEM. Individual data points are
represented in the graphs by scatter points. Sample size was determined by the
minimal number of animals or individual experiment required to obtain statisti-
cally significant results and increased in some cases to improve confidence in the
results obtained. No animal or data point was excluded from the analysis.
Animals. We ablated HDAC1/2 specifically in SCs by crossing mice expressing the
Cre recombinase under control of the Dhh promoter47 with mice expressing floxed
Hdac1 and Hdac248. To induce ablation of HDAC1/2 in OLs of adult mice, mice
expressing floxed Hdac1 and Hdac2 were crossed with mice expressing tamoxifen-
inducible Cre recombinase under control of the OL (and SC)-specific Plp pro-
moter67. To ablate HDAC1/2, mice received daily injections of 2 mg tamoxifen
(Sigma) for five consecutive days. Genotypes were determined by PCR on
genomic DNA.
For all surgical procedures, we used isoflurane (3% for induction, 1.5-2% for
narcosis during the operation) for anesthesia. For analgesia, 0.1 mg/kg/body weight
buprenorphine (Temgesic; Essex Chemie) was administered by i.p. injection 1 h
before surgery, a second time in the evening on the day of surgery and afterwards
every 12 h during 3 days. The mice were placed on a heat pad during the entire
procedure until waking up from anaesthesia. To prevent dehydration of the eyes, a
carbomer liquid eye gel (e.g. Viscotears, Novartis) was used preoperatively. Mice
were shaved either at the height of the hip for sciatic nerve crush lesion or on their
back for lysolecithin lesion of the spinal cord and the field of operation was cleaned
and disinfected. Sciatic nerve crush lesions were carried out on 3 to 4-month old
adult mice (males and females) as follows (by a procedure that we have previously
described41): An incision was made at the height of the hip and the sciatic nerve
was exposed on one side. The nerve was crushed (5 ×10 sec with crush forceps: Ref.
FST 00632-11). The wound was closed using Histoacryl Tissue Glue (BBraun).
After the operation, mice were wrapped in paper towels until recovery from
anaesthesia. Lysolecithin injections were carried out at T8 level as follows (by a
procedure that was previously described68): to prevent dehydration, a single i.p.
injection of 500 µl electrolyte solution with glucose (e.g. Aequifusine, B. Braun
Medical) was administered preoperatively under anesthesia. A 1 cm long skin
incision was made through the lower thoracic spine of the animal, followed by the
separation of the paravertebral muscles from their insertion points at the processi
spinosi over a length of ~3mm to allow access to the spinal cord. The ligamentum
flavum, which connects the dorsal lamella of two adjacent vertebrae, was then
incised and the underlying dura mater was pierced with a needle at the injection
site (right of the central vein). Two microliters of lysolecithin (1% in saline) were
injected focally into the dorsal funiculus and the ventral horn of the spinal cord
with a glass capillary. We used a stereotactic three-way micromanipulator to hold
the syringe and insert it into the spinal cord at a defined angle (15 degrees from
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vertical position) and at a defined depth: the needle of the Hamilton syringe was
slowly inserted into the spinal cord on the right of the central vein at T8 vertebrae
level until resistance was observed. The needle was then withdrawn 0.1 mm, 1 µl of
lysolecithin was injected within 30 s, then the experimenter waited 30 s, the needle
was then moved up 0.5 mm, 1 µl of lysolecithin was injected again within 30 s, the
experimenter waited 1 min, then the needle was withdrawn.
Stratified random allocation in blocks with gender, age, and weight as strata was
used. To minimize heterogeneity, we used littermate mice as control vehicle mice.
Experimenters were blinded to the experimental group (genotype, treatment) and
received only the animal number given at birth by the animal caretaker. Treatment
allocation and collection/analysis of data were done by different persons.
Treatments: 10 mg/kg mocetinostat (HDAC1/2 inhibitor) or 10 mg/kg theophylline
or their respective vehicle were injected in the pelvic cavity after wound closure and
treated again once a day for the indicated time in the figure legends. In mouse pups,
10 mg/kg theophylline or its vehicle were injected subcutaneously once a day for
3 days at P1, P2, and P3 and collection of tissues was carried out at P4. For analysis
in the spinal cord of adult mice (young adults: 3–4-month old; aged mice: 18-
month old; males and females), 10 mg/kg mocetinostat or its vehicle were injected
intrathecally once and animals were sacrificed 24 h later, or 10 mg/kg theophylline
or its vehicle were injected intraperitoneally once a day for 4 days at 10, 11, 12, and
13dpdl. All mice used in this study were from mixed strains backcrossed at least 10
times to C57BL/6 J. Mice were housed in a standard mouse facility with controlled
ventilation (inward airflow, exhaust to the outside), temperature (22 ± 2°C) and
humidity (65 ± 5%) in individually ventilated type II long cages (L 365 mm × B 207
mm ×H 140 mm) containing sawdust bedding, a cardboard cylinder and 2 paper
tissues on the floor, food pellet and water ad libitum. Light cycle: 12:12 h. This
study complies with all relevant ethical regulations concerning animal use, which
was approved by the Veterinary office of the Canton of Fribourg, Switzerland and
the Veterinary office (Landesuntersuchungsamt) of Rheinland-Pfalz, Germany.
Functional recovery experiments. Mice were placed four times on the Rotarod
apparatus at a fixed speed of 15 revolutions per minute to test balance and motor
coordination, at 14 and 30dpl. The duration of each trial was limited to 600 s, and
trials were separated by a 30 min recovery period. Latency to fall from the rotating
beam was recorded and the average of the three trials was used for quantification.
Recovery of sensory function was tested at 14 and 30dpl by toe pinch test: each toe
of the rear foot on the right side (lesioned side) was pinched with equal pressure
applied by the same experimenter using flat tip forceps. Immediate withdrawal was
recorded as functional sensitivity of the pinched toe. In case no toe exhibited
sensitivity, the same test was applied to toes of the contralateral side (uninjured
side), which always resulted in immediate withdrawal. All tests were carried out
with the same experimental animals (10 theophylline-treated mice and 9 vehicle-
treated mice).
Constructs. Expression constructs: pCMV6-AC-mouse eEF1A1-turbo GFP (C-ter)
and GFP backbone constructs were acquired from Origene. Control shRNA
(PLKO) and Stat3 shRNA (SHCLNG-NM_011486, TRCN0000071456) were
acquired from Sigma-Aldrich. Sox10 wild type and mutant constructs, 95, MIC
and HMG and the Mbp promoter-luciferase construct were kindly provided by
Dr. Michael Wegner (University of Erlangen, Germany). K to Q or to R eEF1A1
mutants were generated by site-directed mutagenesis using pCMV6-AC-mouse
eEF1A1-turbo GFP as template. Primers were as follows: K41Q forward, 5′-
GGAATCGACAAGCGAACCATCGACAAGTTTGAGAAAGAGGCTGCTGA
G - 3′, K41Q reverse, 5′- CTCAGCAGCCTCTTTCTCAAACTTGTCGATGGTTC
GCTTGTCGATTCC - 3′, K41R forward, 5′- GGAATCGACAAGCGAACCATC
GAAGAGTTTGAGAAAGAGGCTGCTGAG - 3′, K41R reverse, 5′- CTCAGCA
GCCTCTTTCTCAAACTCTTCGATGGTTCGCTTGTCGATTCC - 3′, K179Q
forward, 5′- CGTTAAGGAAGTCAGCACCTACATTCAGAAAATTGGCTACAA
CCCTGACACAG - 3′, K179Q reverse, 5′- CTGTGTCAGGGTTGTAGCCAATTT
TCTGAATGTAGGTGCTGACTTCCTTAACG - 3′, K179R forward, 5′- CGTTA
AGGAAGTCAGCACCTACATTAGGAAAATTGGCTACAACCCTGACACAG -
3′, K179R reverse, 5′- CTGTGTCAGGGTTGTAGCCAATTTTCCTAATGTAGG
TGCTGACTTCCTTAACG - 3′, K273Q forward, 5′- GCCGAGTGGAGACTG
GTGTTCTCCAACCTGGCATGGTGGTTACCTTTGC - 3′, K273Q reverse, 5′-
GCAAAGGTAACCACCATGCCAGGTTGGAGAACACCAGTCTCCACTCGG
C - 3′, K273R forward, 5′- GCCGAGTGGAGACTGGTGTTCTCAGACCTGGC
ATGGTGGTTACCTTTGC - 3′, K273R reverse, 5′- GCAAAGGTAACCACCA
TGCCAGGTCTGAGAACACCAGTCTCCACTCGGC - 3′. All constructs were
verified by sequencing.
Cell culture. Purified primary rat SC cultures were obtained as follows (method
previously described69): primary SCs were derived from P2 Wistar rat sciatic nerves
and dissociated in 0.3 mg/ml collagenase type I (Sigma-Aldrich) and 2.5 mg/ml
trypsin (Sigma-Aldrich) in DMEM (Invitrogen) at 37°C and 5% CO2/95% air for
1 h. After the addition of DMEM containing 10% FCS (Gibco), cells were cen-
trifuged at 500 × g for 10 min, resuspended in DMEM containing 10% FCS, 1:500
penicillin/streptomycin (Invitrogen), and 10 μM cytosine arabinoside (Sigma-
Aldrich), and plated on plastic dishes coated with poly-D-lysine (Sigma-Aldrich).
After 24 h at 37 °C and 5% CO2/95% air, cells were washed and incubated at 37 °C
and 5% CO2/95% air until they reached confluency in SC proliferating medium:
DMEM containing 10% FCS (Gibco), 1:500 penicillin/streptomycin (Invitrogen),
4 µg/ml crude GGF (bovine pituitary extract, Bioconcept), and 2 µM forskolin
(Sigma). SCs were then purified by sequential immunopanning in plastic dishes
coated with a Thy1.1 antibody70. Identity and purity were checked for each pri-
mary preparation by immunofluorescence of SC-specific markers (p75, Sox10,
Oct6, Krox20, P0, MAG). SCs were grown in proliferation medium: at 37°C and 5%
CO2/95% air. SC de-differentiation culture protocol mimicking SC demyelination
and conversion into repair cells that occur after a PNS lesion was as follows
(previously described41): SCs were first growth-arrested in defined medium (DM58)
for 8 to 15 h, then 1 mM dbcAMP (Sigma) was added to induce differentiation.
Cells were incubated in this medium for another 3 days. The medium was then
changed to DM only without dbcAMP, and RSCs were incubated in this medium
for 3 days (differentiation mimicking adult SC stage). To induce de-differentiation,
cells were then changed to proliferation medium and incubated in this medium for
1 to 3 days (exact duration stated in the figure legends). For some experiments,
10 µM MG132 (proteasome inhibitor), 5 µM TH1834 (Tip60 inhibitor), 0.6 µM
mocetinostat (HDAC1/2 inhibitor), 1 µM theophylline (HDAC2 activator at this
concentration), 1 µM CGS 15943 (adenosine receptor antagonist), 500 µM IBMX
(phosphodiesterase inhibitor), 10 µM rolipram (type 4 phosphodiesterase inhi-
bitor) or their vehicle were added on cells.
Primary OLs were isolated from P1 to P2 rat cortices, which were first diced,
incubated with DNase I and Trypsin for 15 min at 37°C and 5% CO2/95% air, and
then washed and centrifuged at 100 × g for 5 min. The pellet was then re-suspended
and homogenized in DMEM20S71, incubated 10 min on ice, passed through a
70-µm cell strainer and cultured on poly-D-lysine-coated flasks for 10 days in
DMEM20S at 37 °C and 5% CO2/95% air. The flasks were then tightly closed and
shaken first for 1 h at 37 °C to remove microglial cells, and then overnight. OPCs
were collected in the supernatant (this procedure has been previously described71).
Identity and purity were checked for each primary preparation by
immunofluorescence of Sox10 and CC1.
Oli-neu cells66 (kind gift from Dr Jacqueline Trotter, University of Mainz,
Germany) were cultured either in proliferating conditions in DMEM containing
1% horse serum (Gibco) and the following media components: 40 nM Biotin,
100 µg/ml Apo-transferrin, 16 µg/ml Putrescine, 6 ng/ml Progesterone, 4.8 ng/ml
Sodium selenite, 5 µg/ml Insulin (all components from Sigma), 1:500 Penicillin-
Streptomycin (Invitrogen), or in differentiating conditions in DMEM containing
100 µg/ml Apo-transferrin, 16 µg/ml Putrescine, 6 ng/ml Progesterone, 4.8 ng/ml
Sodium selenite, 5 µg/ml Insulin, 40 ng/ml Triiodothyronine (all components from
Sigma), 1:500 Penicillin-Streptomycin (Invitrogen) on poly-D-lysine (Sigma)-
coated dishes.
HEK293 cells were obtained from ATCC and were cultured in DMEM
containing 10% FCS (Gibco) and 1:500 penicillin/streptomycin (Invitrogen) on
poly-D-lysine (Sigma)-coated dishes.
Mycoplasma contamination was not tested, because of the low incidence of
mycoplasma contamination in primary cells, and because mycoplasma
contamination results in inefficiency of transfection, which we did not observe in
our primary cells or in Oli-neu cells or in HEK293 cells.
Ultrathin sections and electron microscopy. Mice were killed with 150 mg/kg
pentobarbital i.p. (Esconarkon; Streuli Pharma AG) and sciatic nerves or spinal
cords were fixed in situ (sciatic nerves) or by perfusion (spinal cords) with 4%
paraformaldehyde (PFA) and 3% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4.
Fixed tissues were post-fixed in 2% osmium tetroxide, dehydrated through a graded
acetone series40, and embedded in Spurr’s resin (Electron Microscopy Sciences).
Ultrathin sections (70-nm thick) were cut. G-ratio (diameter of axon: diameter of
axon+myelin) analyses were done at 12 mm distal to the lesion site for sciatic
nerves and in the lesion site for spinal cords (g ratio average of 60–250 axons
calculated per animal). To delineate the lesion site in the spinal cord and identify
remyelinated axons, the g-ratio was calculated. Axons with a g-ratio above or equal
to 0.835 were classified as remyelinated axons. This g-ratio threshold value was
defined after calculating the g-ratio of axons in non-lesioned mouse spinal cords,
where axons with the thinnest myelin sheath had a g-ratio under or equal to 0.83.
No contrasting reagent was applied. Images were acquired using a Philips CM 100
BIOTWIN equipped with a Morada side-mounted digital camera (Olympus).
Immunofluorescence on mouse tissues and cell cultures. Mouse sciatic nerves
were fixed in situ with 4% PFA for 10 min, dissected, embedded in O.C.T. Com-
pound (VWR chemicals), and frozen at −80°C. Sciatic nerve cryosections (5-μm
thick) were first incubated with acetone for 10 min at −20°C, washed in PBS/0.1%
Tween 20, blocked for 30 min at room temperature (RT) in blocking buffer (0.3%
Triton X-100/ 10% Goat serum/ PBS), and incubated with primary antibodies
overnight at 4°C in blocking buffer. Sections were then washed 3 times in blocking
buffer and secondary antibodies were incubated for 1 h at RT in the dark. Sections
were washed again, incubated with DAPI for 5 min at RT, washed and mounted in
Citifluor (Agar Scientific).
Cells were washed with PBS, fixed for 10 min with 4% PFA at RT, washed again
in PBS, blocked, incubated with antibodies, DAPI, and mounted as
described above.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17243-z ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3420 | https://doi.org/10.1038/s41467-020-17243-z | www.nature.com/naturecommunications 13
For immunofluorescence on spinal cords, mice were deeply anesthetized with a
lethal dose of pentobarbital and perfused with 4% PFA after blood removal with
heparin. Spinal cords were collected 2 mm above and below the lesion site, post-
fixed in 4% PFA for 2 h at RT, incubated in 20% sucrose overnight at 4°C,
embedded in O.C.T. compound, and frozen at -80°C. We used 5-μm cryosections.
Sections were first submitted to antigen retrieval in citrate buffer (10 mM citrate
buffer, 0.05% Tween20, pH6) for 2 h at 65°C, washed, blocked, and incubated with
antibodies, DAPI, and mounted as described above.
Primary antibodies: eEF1A1 (rabbit, 1:200, abcam, cat. # ab157455, lot #
GR231741-13), eEF1A-pan (Acetyl-Lys41) (rabbit, 1:200, AssaybioTech, cat. #
D12106, lot # 410212106), HDAC2 (rabbit, 1:100, Santa-Cruz Biotechnology, cat. #
sc-7899, lot # E0912), Sox10 (rabbit, 1:200, DCS Innovative Diagnostik-Systeme,
cat. # SI058C01, lot # S294), Sox10-Nterm (rabbit, 1:200, kindly provided by Dr.
Michael Wegner), CC1 (mouse, 1:200, Calbiochem, cat. # OP80, lot # 2869730),
Olig2 (goat, 1:200, R&D systems, cat. # AF2418, lot # UPA0512081), 20 S
proteasome subunit (mouse, 1:200, abcam, cat. #ab22674, lot # GR283474-6), MBP
(rat, 1:200, BIO-RAD, cat. #MCA409S, lot # 161031 A), S100 (mouse, 1:100,
GeneTex, cat. # GTX11179, lot # 821503399), F4/80 (rat, 1:200, Lucernachem, cat.
# GTX26640, lot # 821403776), STAT3 (mouse, 1:200, abcam, cat. #ab119352, lot #
GR306889-4). All secondary antibodies were from Jackson ImmunoResearch.
Photos were acquired using a Leica TCS SP-II confocal microscope or a Visitron
VisiScope spinning disk confocal system CSU-W1. Fiji (version 1.0) and Adobe
Photoshop (CC 20.0.8 Release) were used to process images. Single optical sections
or z-series projections (stated in the figure legends) are shown.
Chromatin immunoprecipitation. We used a previously described protocol29 with
modifications: freshly dissected mouse sciatic nerves were minced in 1% for-
maldehyde for 10 min for crosslinking, which was then quenched for 10 min with
glycine to a final concentration of 0.125 M. Samples were then sequentially lysed as
follows: samples were first resuspended in ice cold lysis buffer 1 (50 mM HEPES,
140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% TX-100, protease
inhibitors), rotated at 4°C for 10 min and centrifuged at 4°C at 1350 x g for 5 min.
After discarding the supernatant, the same procedure was repeated in lysis buffer 2
(10 mM Tris, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, protease inhibitors).
The pellet was then resuspended in lysis buffer 3 (10 mM Tris, 100 mM NaCl,
1 mM EDTA, 0.5 mM EGTA, 0.1% Na-Deoxycholate, 0.5% N-Laurylsarcosine,
0.03% SDS, protease inhibitors), incubated on ice for 10 min, homogenized and
diluted by 2 in lysis buffer 3. Chromatin was fragmented by sonication with a
Bioruptor (Diagenode) set at medium power, interval: 30 s on / 45 s off, time:
4 cycles of 10 min, rest of 2 min between cycles. Sonicated chromatin containing
75 µg of proteins and 3 µg of antibodies were used per IP. Sonicated chromatin was
incubated overnight a 4 °C on a rotating wheel, and Magna ChIP™ Protein A+
Protein G Magnetic Beads (Millipore) were added and incubated for 2 h at 4 °C.
Magnetic beads were washed, immunoprecipitated samples were eluted in elution
buffer (50 mM Tris, 10 mM EDTA, 1% SDS), crosslinking was reversed at 65 °C for
8–16 h and after RNase and proteinase K treatment, the DNA was purified using a
PCR clean-up kit (Macherey-Nagel). Quantitative real-time PCR analyses were
performed with an ABI 7000 Sequence Detection System (Applied Biosystems)
using FastStart SYBR Green Master (Sigma), according to the manufacturer’s
recommendations. A dissociation step was added to verify the specificity of the
products formed. Primers sequences were as follows: Krox20 MSE, forward, 5′-
TTTCGTCTTTGGGCTCATTC-3′, reverse, 5′-AGCCCTTCACAAAGCTGAA
A-3′, P0 intron 1, forward, 5′-GTGCTGGACTCGGCATCTTT-3′, reverse, 5′-
CCAGGTTACCATGACTGGGG-3′. For Sox10 IP, we used 2 µg/IP of anti-Sox10
antibody (rabbit, DCS Innovative Diagnostik-Systeme, cat. # SI058C01) and as
negative control IP we used 2 µg/IP of anti-GFP antibody (rabbit, Abcam, cat #
ab290, lot # GR196475-1).
Western blot and immunoprecipitation. For all in vivo Western blots and
immunoprecipitations, we have collected the injured sciatic nerve from the lesion
site to around 12 mm distal to the lesion site (region where the nerve splits into the
three branches of tibial, sural and common peroneal nerves). We have collected the
same region of the contralateral nerve as internal control for each animal. After
perineurium removal, sciatic nerves were frozen in liquid nitrogen, pulverized with
a chilled mortar and pestle, lysed in radioimmunoprecipitation assay (RIPA) buffer
(10 mM Tris/HCl, pH 7.4, 150 mM NaCl, 50 mM NaF, 1 mM NaVO4, 1 mM
EDTA, 0.5% wt/vol sodium deoxycholate, and 0.5% Nonidet P-40) for 30 min on
ice, and centrifuged to pellet debris. Supernatants were collected.
Cells were washed once in PBS, lysed in RIPA buffer for 15 min on ice, and
centrifuged to pellet debris. Sciatic nerves and cell lysates were submitted to SDS-
PAGE and analyzed by Western blotting.
Primary antibodies used: eEF1A1 (rabbit, 1:5000, Abcam, cat. # ab157455),
eEF1A-pan (Acetyl-Lys41) (rabbit, 1:500, Labforce/AssaybioTech, cat. # D12106),
HDAC2 (mouse, 1:1000, Sigma, cat. # H2663, lot # 096M4799V), Sox10 (rabbit,
1:250, DCS Innovative Diagnostik-Systeme, cat. # SI058C01), Sox10 (mouse,
1:1000, Abcam, cat. # ab216020, lot # GR3272630-2), GAPDH (glyceraldehyde-3-
phosphate-dehydrogenase, mouse, 1:5000, Genetex, cat. # GTX28245, lot #
821705388), P0 (chicken, 1:1000, Aves Labs, cat. # PZO, lot # PZO0308), Krox20
(rabbit, 1:500, provided by Dr. Dies Meijer, University of Edinburgh, Ref. 72),
Lamin A/C (mouse, 1:5000, Sigma-Aldrich, cat. # SAB4200236, lot # 055M4822V),
KAT5/Tip60 (rabbit, 1:1000, abcam, cat. #ab151432, lot # GR113712-14), STAT3
(mouse, 1:5000, abcam, cat. #ab119352, lot # GR306889-4), GFP (mouse, 1:2000,
Origene, cat. # TA150041, lot # W002).
All secondary antibodies were from Jackson ImmunoResearch: light chain-
specific goat anti-mouse-HRP (horse radish peroxidase) and goat anti-rabbit-HRP,
and heavy chain-specific goat anti-chicken-HRP.
For non-denaturing IPs, tissues were prepared and lysed as described above in
the following RIPA buffer: 10 mM Tris/HCl, pH7.4, 150 mM NaCl, 50 mM NaF,
100 mM Na3VO4, 1 mM EDTA, 0.5% Nadeoxycholate, 0.5% NP40. For denaturing
IPs, tissues were lysed in 10 mM Tris/HCl, pH7.4, 1% SDS, boiled, mixed with 9
volumes of RIPA buffer, reboiled, and centrifuged. Lysates were pre-cleared for 1 h
with 30 µl protein A/G PLUS agarose beads (Santa-Cruz Biotechnology). One
milliliter of cleared lysates was rotated overnight at 4° C with immunoprecipitating
antibodies: 2 µg of Sox10 (rabbit, DCS Innovative Diagnostik-Systeme, cat. #
SI058C01), eEF1A1 (rabbit, abcam, cat. # ab157455), EEF1A2 (rabbit, proteintech,
cat. # 16091-1-AP, lot # 1370), GFP (rabbit, Abcam, cat. # ab290, lot # GR196475-
1), Flag (mouse, Sigma, cat. # F1804, lot # SLBM0089V), SUMO-1 (mouse, Santa-
Cruz Biotechnology, cat. # sc-5308, lot # F-1913) antibodies were used per nerve.
We used rabbit anti-GFP or mouse anti-Flag antibodies as control IPs. Forty
microliters of beads were added, and samples were rotated for 1 h at 4°C.
Immunoprecipitates were pelleted, washed four times with RIPA buffer, eluted
with 15 µl 0.1% formic acid and neutralized with 1.5 M Tris, pH 8. Six microliters
of Laemmli buffer were added and samples were boiled for 10 min. Analysis was
done by Western blot.
Luciferase gene reporter assay. Forty to fifty-percent confluent Oli-neu cells in
12-well plates were transfected either in proliferating or in differentiating medium
with Fugene 6 (Promega) at a 3:1 ratio Fugene 6:DNA, according to the manu-
facturer’s recommendations with the following modification: the DNA was incu-
bated in Optimem for 5 min at room temperature before addition of Fugene 6. The
mix Fugene 6:DNA was then incubated for 25 min at room temperature before
being added to the cells. Cells were lysed 24 h after transfection in 180 µl Reporter
Lysis Buffer (Promega) and assayed for luciferase activity. Twenty microliters of
lysate were subjected to 2 consecutive injections of each 25 µl luciferase substrate
and values were recorded after an integration time of 30 s. Efficiency of transfection
was evaluated by measuring beta-galactosidase activity of a co-transfected beta-gal
construct (Promega). Oli-neu cells were co-transfected with 2 µg of the luciferase
construct pGL2-Mbp promoter (kind gift from Dr M. Wegner) or empty pGL2
(Promega), 2 µg of the overexpressing construct pCMV6-AC-mouse eEF1A1-turbo
GFP (C-ter) or GFP backbone (Origene) or pCMV6-AC-mouse eEF1A1K273Q-
turbo GFP (C-ter), and 300 ng beta-gal construct. Luciferase activity was first
normalized to beta-galactosidase activity and then normalized to the empty pGL2
luciferase control (transfected with the overexpressing construct at the same ratio
Fugene 6:DNA). For beta-galactosidase activity, we followed the instructions of the
manufacturer (Promega). Briefly, 50 µl Assay Buffer 2x was added to 50 µl lysate,
and beta-galactosidase activity was recorded after a 15-20 min incubation time at
37°C. Endogenous beta-galactosidase activity (as determined from cells only
transfected with overexpressing construct at the same ratio Fugene 6:DNA) was
subtracted.
Mass spectrometry analyses. The mass spectrometry experiment and method
after IP of acetyl-lysine at 1dpl in mouse sciatic nerves treated with mocetinostat or
vehicle has been previously published41. The data of the present study results from
a different analysis of the previous experiment by Protein Match Score Summation.
For identification of eEF1A1 binding partners by mass spectrometry analysis,
the collected beads were heated in SDS-PAGE loading buffer containing 1 mM
DTT for 10 min at 75°C. After alkylation using 5.5 mM iodoacetamide for 10 min
at room temperature the samples were centrifuged and the supernatants were
loaded on 4-12% gradient gels (NuPAGE, Thermo Fisher) for protein separation.
After staining, each gel lane was cut into 7 slices, the proteins were in-gel digested
with trypsin (Promega) and the resulting peptide mixtures were processed on
STAGE tips and analyzed by LC-MS/MS. The LC-MS measurements were
performed on a QExactive Plus mass spectrometer coupled to an EasyLC 1000
nanoflow-HPLC. Peptides were separated on fused silica HPLC-column tip (I.D.
75 µm, New Objective, self-packed with ReproSil-Pur 120 C18-AQ, 1.9 µm (Dr.
Maisch) to a length of 20 cm) using a gradient of A (0.1% formic acid in water) and
B (0.1% formic acid in 80% acetonitrile in water). The mass spectrometer was
operated in the data-dependent mode; after each MS scan (mass range m/z= 370 –
1750; resolution: 70000) a maximum of ten MS/MS scans were performed using a
normalized collision energy of 25%, a target value of 1000 and a resolution of
17500. The MS raw files were analyzed using MaxQuant Software version 1.4.1.2
for peak detection, quantification, and peptide identification using a full length
UniProt mouse database (April, 2016) and common contaminants such as keratins
and enzymes used for in-gel digestion as reference. Carbamidomethylcysteine was
set as fixed modification and protein amino-terminal acetylation, lysine acetylation,
and oxidation of methionine were set as variable modifications. The MS/MS
tolerance was set to 20 ppm and three missed cleavages were allowed using trypsin/
P as enzyme specificity. Peptide and protein FDR based on a forwards-reverse
database were set to 0.01, minimum peptide length was set to 7, and minimum
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number of peptides for identification of proteins was set to one, which must be
unique. The “match-between-run” option was used with a time window of 1 min.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1–5, Figs. 7–9 and Supplementary Figs. 1, 4, 5, 7, 9, 11 are
provided as a Source Data file. The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE [1] partner repository with the dataset
identifiers PXD010552 [http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=
PXD010552], PXD005383 [http://proteomecentral.proteomexchange.org/cgi/GetDataset?
ID= PXD005383] and PXD017579 [http://proteomecentral.proteomexchange.org/cgi/
GetDataset?ID= PXD017579]. There is no restriction on data availability. Source data are
provided with this paper.
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